Lipid encapsulated cisplatin - LiPlasome Pharma

Drug Profile

Lipid encapsulated cisplatin - LiPlasome Pharma

Alternative Names: LiPlaCis

Latest Information Update: 05 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LiPlasome Pharma
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 31 Jan 2018 Interim efficacy data from a phase I/II trial in Breast cancer released by Oncology Venture
  • 19 Sep 2017 Oncology Veture announces intention to submit regulatory application to US FDA
  • 19 Sep 2017 Early efficacy data from phase II portion of a phase I/II trial in Solid tumours released by Medical Prognosis Institute and Oncology Venture
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top